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Hepatitis B viral (HBV) infection is one of the major liver diseases of mankind and is a serious global public health problem because of its high morbidity and 
mortality [1]. The biomarkers associated with HBV infection 
helps in the identification of disease, stratification of chronic 
hepatitis and therapy [2]. Acute HBV infection in children is 
mostly asymptomatic; although, some may present with fatigue, 
anorexia, malaise, arthralgia, or skin lesions. Extrahepatic 
manifestations associated with HBV infection are polyarteritis 
nodosa, glomerulonephritis, and aplastic anemia. Most of them 
recover, but certain children go into complications such as acute 
liver failure, chronic HB, cirrhosis, and hepatocellular carcinoma 
which are associated with high mortality [3,4].
Treatment of acute HBV infection is largely supportive. 
Treatment of chronic HBV infection is in evolution; no one drug 
currently achieves consistent, complete eradication of the virus. 
Therefore, prevention is the mainstay of treatment [3]. Apart from 
screening blood donors for HB, following universal precautions 
while handling blood products, passive immunization with HB 
immunoglobulin, active immunization with HB vaccine is the 
most effective means of preventing the infection. There has been a 
significant decrease in the prevalence of HBV infection in countries 
which have adopted the immunization program diligently.
However, immunization is also not 100% effective due 
to various reasons. Despite immunization with three doses 
of HB vaccine in infancy, 5–10% of children do not show 
seroconversion [5]. Among babies born to HBs antigen (HBsAg) 
positive mothers who receive active and passive immunization 
at birth, 5–10% still develops HB infection [6]. Formation of 
vaccine escapes mutants which will decrease the efficacy of 
existing vaccine and eventually cause evasion of the vaccine.
The recombinant HBV yeast derived vaccine has a number 
of limitations that justify the development of new HBV vaccines 
such as the need for multiple doses, lack of long-lasting immunity, 
inability to induce both humoral and cellular immunity against 
the antigenic targets of major genotypes of virus, and incomplete 
protection in vaccinees where a group of non-responders does 
exist and vaccine is therapeutically ineffective [7]. Hence, this 
study was designed to assess the prevalence of seroprotective 
antibodies against HBV in previously immunized children 
attending a community hospital.
MATERIALS AND METHODS
This cross-sectional study was done in a tertiary care canter 
serving the urban and rural population around Chennai from 
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January 2016 to April 2016. Approval from hospital authority, 
scientific committee and ethics committee were taken before 
starting the study. The sample size was calculated using the 
following formula and was estimated to be 196.
( )t² p 1 p
n
m²
× −
=
( )2.576 2.576 0.92 1 0.92
n
0.05²
× × −
=
n = 196
Where n = required sample size, the expected proportion or 
seroconversion and seroprotection rate (p) = 0.92, t = confidence 
level at 99% (standard value of 2.576), m = margin of error at 1% 
(standard value of 0.05) at desired confidence level of 99%.
This study was conducted on children between 1 and 12 years 
of age attending the pediatric outpatient department. Children, 
who had a complete record of vaccination duly, endorsed in 
vaccination cards, were included in the study. Children <1 year 
of age and children with incomplete vaccination or without 
vaccination cards were excluded. A questionnaire was used 
and details regarding the child’s age, gender, date of birth, data 
concerning HB vaccination status, and vaccination cards were 
revised for date and dose intervals of HB vaccine, family history 
of HB and if mother is HBsAg positive, details of active and 
passive immunization given in the newborn period and follow-up 
visits were filled up and analyzed.
After obtaining informed consent, about 2 ml of blood sample 
was withdrawn from each participant. Serum samples were a 
aliquoted into labeled tubes and stored at 2°to8°C until laboratory 
examination. After blood sample collections, plasma samples 
were separated and tested for anti-HBs using enzyme-linked 
immune sorbent assay following the manufacturer’s protocol. As 
per the WHO standards, anti-HBs antibody titers of >10 mIU/ml 
were taken as cutoff for protective level and samples showing 
titers <10 mIU/ml were considered nonprotective. Samples 
showing anti-HBs titers above 1mIU/ml were considered to have 
seroconverted.
The test principle was based on antigen sandwich enzyme 
immunoassay. Patient’s serum or plasma sample was added to 
the microcells together with HBsAg conjugated to Horseradish 
peroxidase (HRP-Conjugate). In case of presence of anti-HBs 
in the sample, the pre-coated and conjugated antigens will be 
bound to the two variable domains of the antibody, and during 
incubation, the specific immunocomplex formed is captured 
on the solid phase. After washing to remove the sample and 
unbound HRP-Conjugates, chromogen solutions containing 
tetramethylbenzidine and urea peroxide are added to the wells. In 
the presence of the antigen-antibody-antigen (HRP) “sandwich” 
complex, the colorless chromogens are hydrolyzed by the bound 
HRP-Conjugate to a blue-colored product. The blue color turns 
yellow after stopping the reaction with sulfuric acid. The amount of 
color intensity can be measured and is proportional to the amount 
of antibody captured in the wells, and to the sample, respectively. 
The sensitivity of the test was 100%, and specificity was 98.8%.
Data were entered in Microsoft Excel sheet, and statistical 
analysis was done using SPSS (Statistical Package for the Social 
Sciences) version19.0. Chi-square tests were done to compare 
the categorical variables seroconversion rate, seroprotection 
rate among the immunized children. The study population was 
divided into four age groups: 1–3 years, 4–6 years, 7–9 years, 
and 10–12 years. Anti-HBs levels were classified as <10 mIU/ml, 
11–100 mIU/ml, 101–500 mIU/ml, and >500 mIU/ml and were 
studied among the four individual age groups and results were 
interpreted. The median values of anti-HBs titers were calculated 
using Mann–Whitney U-test. For continuous measurements of 
anti-HBs levels, the comparison between age groups were done 
using Mann–Whitney U-test and Fischer’s Test. p<0.05 was 
considered statistically significant (Fig. 1).
RESULTS
A total of 196 children between 1 and 12 years of age who had 
completed all the three doses of HB vaccine series were enrolled 
in the study. In this study, the majority of the children were falling 
under 1–3 years age group (Table 1). Of 196 children studied 
104 (53%) were males and 92 (46.9%) were females. 185 (94.38%) 
children received vaccination through private institutions and 
11 (5.61%) children received through government hospitals. Of 
196 children, 185 children had taken birth, 6 weeks, 6-month 
schedule whereas 11 children had taken 6 weeks, 10 weeks, and 
14-week schedule (Table 2). In our study, none of the children had 
a history of jaundice in family members and none of the children 
were born to HBsAg positive mothers
Of 196 children, 180 children showed seroconversion with 
an anti-HBs level above 1 mIU/ml, and the seroconversion 
rate was 91.8%. The remaining 16 children did not 
seroconvert, and the percentage of non seroconversion was 
Figure 1: Study flow chart
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Table 1: Distribution of seroprotection among four individual age groups
Seroprotection Age group Total p
1–3 years (%) 4–6 years (%) 7–9 years (%) 10–12 years (%)
Yes 81 (90.0) 40 (80) 16 (64) 7 (46.7) 144 (80.0) <0.001
No 9 (10.0) 10 (20) 9 (36) 8 (53.3) 36 (20.0)
Total 90 (100) 50 (100) 25 (100) 15 (100 180 (100)
Table 2: Distribution of seroprotection based on HBV immunization schedule
Seroprotection Immunization schedule Total (%) p
0, 6 weeks, 6 months (%) 6 weeks, 10 weeks, 14 weeks (%)
Yes 141 (82.9) 3 (30) 144 (80.0) 0.001
No 29 (17.1) 7 (70) 36 (20.0)
Total 170 (100) 10 (100) 180 (100)
HBV: Hepatitis B viral
Table 3: Median anti‑HBs titers in each age group
Age (years) Number of 
children
Anti‑Hbs levels (mIU/ml) p§
Median IQR
1–3 97 333.5 (85.41,422.75) <0.001
4–6 54 63.2 (9.31,343.05)
7–9 28 17.12 (3.51,105.56)
10–12 17 7.69 (2.5,31.04)
Overall 196 169.75 (8.90,382.05)
§Mann–Whitney U‑test. HBs: Hepatitis B surface, IQR: Interquartile range
8.2%. Of 180 seroconverted children, 36 (20%) had anti-HBs 
levels <10 mIU/ml (non-protective level) while 144 (80%) had 
anti-HBs levels above 10 mIU/ml (protective level). As the age 
advances, the seroprotective rate decreases as shown in Table 3. 
The seroprotective rates of children among 1–3 years age group 
were 90%, 4–6 years age group were 80%, 7–9 years age group 
were 64%, and 10–12 years age group were 46.7%. The difference 
was statistically significant (p<0.001).
Among the study population, males had a seroprotection rate 
of 81.6% while females had a seroprotection rate of 78% and the 
difference was not statistically significant. Of 144 seroprotected 
children, 141 children had taken 0, 6 weeks, and 6 months 
schedule whereas 3 had taken 6 weeks, 10 weeks, and 14 weeks 
schedule. Of 36 children who are not seroprotected, 29 had taken 
0, 6 weeks, 6 months schedule and 7 had taken 6 weeks, 10 weeks, 
and 14 weeks schedule. The seroprotective rates were superior 
in children who were vaccinated with 0, 6 weeks, and 6 months 
schedule than in children with 6 weeks, 10 weeks, and 14 weeks 
(p<0.001) as shown in Table 2.
Of 185 children who received vaccination through government 
hospitals, 43 children had anti-HBs titers <10 mIU/ml and 
142 children had anti-HBs titers>10 mIU/ml. Of 11 children 
vaccinated in private sector, 8 had anti-HBs titers<10 mIU/ml, 
and 3 children had anti-HBs titers>10 mIU/ml. Seroprotection 
rates were higher in children vaccinated through private institutions 
than government hospitals (p<0.001). The overall median anti-HBs 
levels were 169.75 mIU/ml, and the interquartile range was 8.9 and 
384.05 mIU/ml. The median anti-HBs levels among individual age 
groups are shown in Table 4. With the advancing age, the median 
anti-HBs levels tend to decrease significantly (p<0.001).
DISCUSSION
HB is a global health problem with variable prevalence in different 
parts of the world. Various studies conducted in India showed that 
the prevalence of hepatitis as 2.4% whereas in tribal population, 
the figures are much higher (15.9%). It is estimated that India 
hosts about 40 million chronic HB carriers, which is almost 4% 
of the entire population. Age at the time of acquisition plays an 
important role in predicting the carrier state. HB acquired during 
infancy is responsible for a very high risk of cirrhosis in later life. 
HB is a preventable disease and vaccination at birth can eradicate 
the disease if vaccine strategy is effectively implemented.
In our study, 145 of 196 children had anti-HBs >10 mIU/ml 
and 51 children had anti-HBs <10 mIU/ml. These results were 
comparable to a study done by Afzal et al. [6], where 133 children 
had anti-HBs >10 mIU/ml and 61 had anti-HBs <10 mIU/ml. In 
our study, 180 children showed seroconversion (anti-HBs>1 mIU/
ml), and seroconversion rate was 91.8%. These results were 
comparable with study done by Khan in Bangladesh [8]. The 
seroconversion rate was 92.4% in males, and 89.1% in females 
and these results were compared with results of the study by 
Zamani et al. [9].
Of 180 children who had seroconverted, 36 (20%) had non-
protective levels while 144 (73.97%) had protective levels of 
anti-HBs. The seroprotection rate in our study was 80%, and it 
correlates with the results of study done by Saffar and Rezai [10] 
and Sugunan et al. [11] As the age advances, the seroprotective 
rate decreases and this was comparable with the results of various 
other studies [12-17]. The GMT of anti-HBs was 7.69 mIU/ml 
which is very less compared to the GMT of studies done by Saffar 
et al. [10] In our study, seroprotection after 5 and 10 years were 
64.7% and 46.7% which is lesser than the study reports of Gilca 
et al. [18] (88.2% and 86.4%, respectively). This difference may 
be due to the differences in the type of vaccine used, amount of 
the antigen delivered, and the population immunized.
A similar study was done in Turkey for children between age 
group 2 and 12 years by Alavian [19]. They reported that the rate 
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of persistent protective level of anti-HBs titers varied from 33% 
to 79%, 5 years after vaccination and their results were consistent 
with our study results. In another study done by Eldesoky 
et al. [20] in Egypt, the persistence of protective antibody titer 
was 53% in vaccinated children aged 6–10 years. In our study, the 
seroprotection rates were 81.6% and 78% in males and females, 
respectively. This was consistent with the study reports of el-sawy 
and Mohamed [21].
In our study, there was a significant decline in anti-HBs titers 
as the age advances (p<0.001). These results were consistent 
with the study results of Hosseine et al. [12] in Iranian children 
and El-Sayed et al. [22] in Egyptian children. The seroprotective 
rates were superior in children who took birth, 6 weeks, 6 months 
schedule than in children who took 6 weeks, 10 weeks, and 
14 weeks (p<0.001). However, this was different from the study 
done by Wouters et al. [23]. They compared the immunogenicity 
of schedules administered at 0, 1, 4 months and 0, 1, 6 months 
among commercial sex workers and found equal efficacy between 
both schedules.
In our study, parental awareness about the vaccine was good. 
A study conducted in Vellore showed that the parental awareness 
of vaccine availability was 71% and knowledge about the vaccine 
was better for HBV vaccine than other vaccines [24]. Afzal 
et al. [6] showed that all children who received private procured 
HB vaccine achieved protected antibody levels and the difference 
between the vaccines procured from public sector and private 
sector was statistically significant (p=0.028). These results were 
similar to our study results.
The overall median anti-HBs level in our study was 
169.75 mIU/ml, which is lower than the mean GMT of anti-
HBs levels in children aged 1–15 years (232.64 mIU/ml) in a 
study done by Hosseine et al. [12]. With the advancing age, the 
median anti-HBs levels tend to decrease significantly (p<0.001). 
These results are comparable to a study conducted by Aghakhani 
et al. [25] in children aged 8 months to 15 years. They showed 
that the mean anti-HBs titer declined with post-vaccination time 
(to 66 mIU/ml in 1 year, 60 mIU/ml in 5 years, and 40 mIU/
ml in 10 years to 37 mIU/ml in 15 years after vaccination). In 
another study by Dahifar et al., the GMT of anti-HBs 5 years after 
vaccination decreased to 153 mIU/ml [26].
Our study also has some limitations. First, the sample size 
was small. Second, we could not check the HBsAg levels, HB 
core antibody levels and liver function tests for children who did 
not show seroconversion due to limited resources and funding. 
Although we obtained significant association for variables in 
relation to place of immunization and immunization schedule, we 
believe that studies with larger sample sizes would be required 
to further validate our results. We also suggest that children who 
have low titers should be followed up for breakthrough infection 
and occurrence of chronic infection which may occur if there 
is a lapse of immunological memory. Children who have not 
seroconverted should be evaluated in detail including all HBV 
biomarkers, and if HBsAg is negative, they should be revaccinated 
with three doses of HB vaccine and rechecked for seroprotective 
status 4 weeks after the last dose.
CONCLUSION
Overall, seroprotection in our study was lower than the previously 
reported rates; however, it was acceptable in children between 1 
and 3 years of age. There was an exponential drop in seroprotection 
rates with increasing age; however, this does not indicate the need 
for a booster because of the immunological memory. The dosing 
of 0, 1, and 6 months schedule showed a better seroprotection 
endorsing the view that it is better to immunize neonates soon 
after birth.
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